Optimising first- and second-line treatment strategies for untreated major depressive disorder — the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial
Open Access
- 11 July 2018
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 16 (1) , 103
Abstract
For patients starting treatment for depression, current guidelines recommend titrating the antidepressant dosage to the maximum of the licenced range if tolerated. When patients do not achieve remission within several weeks, recommendations include adding or switching to another antidepressant. However, the relative merits of these guideline strategies remain unestablished. This multi-centre, open-label, assessor-blinded, pragmatic trial involved two steps. Step 1 used open-cluster randomisation, allocating clinics into those titrating sertraline up to 50 mg/day or 100 mg/day by week 3. Step 2 used central randomisation to allocate patients who did not remit after 3 weeks of treatment to continue sertraline, to add mirtazapine or to switch to mirtazapine. The primary outcome was depression severity measured with the Patient Health Questionnaire-9 (PHQ-9) (scores between 0 and 27; higher scores, greater depression) at week 9. We applied mixed-model repeated-measures analysis adjusted for key baseline covariates. Between December 2010 and March 2015, we recruited 2011 participants with hitherto untreated major depression at 48 clinics in Japan. In step 1, 970 participants were allocated to the 50 mg/day and 1041 to the 100 mg/day arms; 1927 (95.8%) provided primary outcomes. There was no statistically significant difference in the adjusted PHQ-9 score at week 9 between the 50 mg/day arm and the 100 mg/day arm (0.25 point, 95% confidence interval (CI), − 0.58 to 1.07, P = 0.55). Other outcomes proved similar in the two groups. In step 2, 1646 participants not remitted by week 3 were randomised to continue sertraline (n = 551), to add mirtazapine (n = 537) or to switch to mirtazapine (n = 558): 1613 (98.0%) provided primary outcomes. At week 9, adding mirtazapine achieved a reduction in PHQ-9 scores of 0.99 point (0.43 to 1.55, P = 0.0012); switching achieved a reduction of 1.01 points (0.46 to 1.56, P = 0.0012), both relative to continuing sertraline. Combination increased the percentage of remission by 12.4% (6.1 to 19.0%) and switching by 8.4% (2.5 to 14.8%). There were no differences in adverse effects. In patients with new onset depression, we found no advantage of titrating sertraline to 100 mg vs 50 mg. Patients unremitted by week 3 gained a small benefit in reduction of depressive symptoms at week 9 by switching sertraline to mirtazapine or by adding mirtazapine. ClinicalTrials.gov, NCT01109693 . Registered on 23 April 2010.Keywords
Funding Information
- Ministry of Health, Labour and Welfare (H-22-Seishin-Ippan-008)
- Japan Foundation for Neurosciences and Mental Health
This publication has 45 references indexed in Scilit:
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disordersThe World Journal of Biological Psychiatry, 2013
- The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phaseTrials, 2012
- Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocolTrials, 2011
- Born to Be Criminal? What to Make of Early Biological Risk Factors for Criminal BehaviorAmerican Journal of Psychiatry, 2010
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorderThe British Journal of Psychiatry, 2006
- The PHQ-9Journal of General Internal Medicine, 2001
- Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine aloneActa Psychiatrica Scandinavica, 2001
- Does increasing dose improve efficacyin patients with poor antidepressantresponse: a reviewActa Psychiatrica Scandinavica, 2000
- Effectiveness of antidepressantsThe British Journal of Psychiatry, 1999